含安美汀方案治疗耐多药结核病的近期疗效初步观察

目的 对多耐药 (MDR)肺结核产生机理及应用二线结核药治疗方案进行探讨，并阐明安美汀作用机制。方法 采用中国防痨协会制定的结核分枝杆菌多耐药标准及疗效判定，对我院10年来72例多耐药肺结核，应用抗结核二线药 (对照组)与含安美汀抗结核二线药方案 (治疗组)进行比较。结果 对72例多耐药肺结核病例进行分析，治疗组与对照组6个月胸片好转率及痰菌阴转率相比有显著差异 (P＜0.05)。结论 安美汀是一种新的、有效的、安全的抗结核药物。

Preliminary observation of therapeutic effect of the regimen containing augmentin on multidrug resistant pulmonary tuberculosis

Objective To explore the mechanism of MDR-TB and treatment regiment using second line antituberculosis drugs,to illustrate the effective mechanism of augmentin.Methods The standard and treatment outcome of MDR-TB designed by Chinese Antituberculosis Association was used to compare the curative effect of treatment regimens using second line antituberculosis drugs containing augmentin(expermental group)and without augmentin(control group) to treat 72 cases with MDR-TB admitted in our hospital in the last 10 years.Results The comparison of treatment outcome of the 72 MDR-TB cases showed that,after 6 months treatment the improving rate of chest X-ray and sputum conversion were more obvious in experimental group than in control group.There is significantly difference between the two groups (P<0.05) .Conclusion Augmentin is new,effective and safe antituberculosis drug.